Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Pharmacokinetic study of the oral fluorouracil antitumor agent S-1 in patients with impaired renal function.

Goto K, Fujiwara Y, Isobe T, Chayahara N, Kiyota N, Mukohara T, Tsubata Y, Hotta T, Tamura K, Yamamoto N, Minami H.

Cancer Sci. 2019 Jun;110(6):1987-1994. doi: 10.1111/cas.14025. Epub 2019 May 11.

2.

Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE).

Chayahara N, Mukohara T, Tachihara M, Fujishima Y, Fukunaga A, Washio K, Yamamoto M, Nakata K, Kobayashi K, Takenaka K, Toyoda M, Kiyota N, Tobimatsu K, Doi H, Mizuta N, Marugami N, Kawaguchi A, Nishigori C, Nishimura Y, Minami H.

Oncologist. 2019 Mar 19. pii: theoncologist.2019-0156. doi: 10.1634/theoncologist.2019-0156. [Epub ahead of print]

PMID:
30890624
3.

Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipsin.

Goto H, Shimono Y, Funakoshi Y, Imamura Y, Toyoda M, Kiyota N, Kono S, Takao S, Mukohara T, Minami H.

Oncogene. 2019 Feb;38(6):767-779. doi: 10.1038/s41388-018-0477-8. Epub 2018 Sep 3.

PMID:
30177835
4.

Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.

Goto H, Kiyota N, Otsuki N, Imamura Y, Chayahara N, Suto H, Nagatani Y, Toyoda M, Mukohara T, Nibu KI, Kasahara T, Ito Y, Miya A, Hirokawa M, Miyauchi A, Minami H.

Auris Nasus Larynx. 2018 Dec;45(6):1249-1252. doi: 10.1016/j.anl.2018.05.003. Epub 2018 May 18.

PMID:
29779695
5.

Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging.

Nishimura M, Hayashi M, Mizutani Y, Takenaka K, Imamura Y, Chayahara N, Toyoda M, Kiyota N, Mukohara T, Aikawa H, Fujiwara Y, Hamada A, Minami H.

Oncotarget. 2018 Apr 6;9(26):18540-18547. doi: 10.18632/oncotarget.24928. eCollection 2018 Apr 6.

6.

3D Culture Represents Apoptosis Induced by Trastuzumab Better than 2D Monolayer Culture.

Tatara T, Mukohara T, Tanaka R, Shimono Y, Funakoshi Y, Imamura Y, Toyoda M, Kiyota N, Hirai M, Kakeji Y, Minami H.

Anticancer Res. 2018 May;38(5):2831-2839.

PMID:
29715106
7.

Expression of programmed death-1 in sentinel lymph nodes of breast cancer.

Tatara T, Mukohara T, Shimono Y, Yamasaki T, Imamura Y, Funakoshi Y, Toyoda M, Kiyota N, Takao S, Kono S, Kakeji Y, Minami H.

J Surg Oncol. 2018 May;117(6):1131-1136. doi: 10.1002/jso.24937. Epub 2017 Nov 28.

PMID:
29193094
8.

Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report.

Yamashita Y, Tanaka Y, Kono S, Nishimura M, Mukohara T, Morinaga Y, Hara S, Takao S.

Breast Care (Basel). 2017 Mar;12(1):45-47. doi: 10.1159/000457948. Epub 2017 Feb 28.

9.

Malignant melanoma with bone marrow involvement diagnosed from hypercalcemia: Development of a neural cell adhesion molecule stain.

Fukumoto T, Sakaguchi M, Oka M, Nishimura M, Mukohara T, Nishigori C.

J Dermatol. 2017 May;44(5):e105-e106. doi: 10.1111/1346-8138.13718. Epub 2016 Dec 10. No abstract available.

PMID:
27943396
10.

Evaluation of the risk of lymphomagenesis in xenografts by the PCR-based detection of EBV BamHI W region in patient cancer specimens.

Mukohyama J, Iwakiri D, Zen Y, Mukohara T, Minami H, Kakeji Y, Shimono Y.

Oncotarget. 2016 Aug 2;7(31):50150-50160. doi: 10.18632/oncotarget.10322.

11.

Effect of Xenotransplantation Site on MicroRNA Expression of Human Colon Cancer Stem Cells.

Mukohyama J, Shimono Y, Yamashita K, Sumi Y, Mukohara T, Minami H, Kakeji Y.

Anticancer Res. 2016 Jul;36(7):3679-86.

PMID:
27354640
12.

The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer.

Nishimura M, Toyoda M, Takenaka K, Imamura Y, Chayahara N, Kiyota N, Mukohara T, Kotake T, Tsuji A, Saito K, Saito Y, Minami H.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1165-70. doi: 10.1007/s00280-016-3026-6. Epub 2016 Apr 21.

13.

Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer.

Kataoka T, Kiyota N, Shimada T, Funakoshi Y, Chayahara N, Toyoda M, Fujiwara Y, Nibu K, Komori T, Sasaki R, Mukohara T, Minami H.

Auris Nasus Larynx. 2016 Dec;43(6):677-84. doi: 10.1016/j.anl.2016.02.012. Epub 2016 Mar 15.

PMID:
26992271
14.

A prospective study on the efficacy of two-dose influenza vaccinations in cancer patients receiving chemotherapy.

Sanada Y, Yakushijin K, Nomura T, Chayahara N, Toyoda M, Minami Y, Kiyota N, Mukohara T, Kawamoto S, Ito M, Matsuoka H, Minami H.

Jpn J Clin Oncol. 2016 May;46(5):448-52. doi: 10.1093/jjco/hyw020. Epub 2016 Mar 13.

PMID:
26977053
15.

Validity of new methods to evaluate renal function in cancer patients treated with cisplatin.

Funakoshi Y, Fujiwara Y, Kiyota N, Mukohara T, Shimada T, Toyoda M, Imamura Y, Chayahara N, Tomioka H, Umezu M, Otsuki N, Nibu K, Minami H.

Cancer Chemother Pharmacol. 2016 Feb;77(2):281-8. doi: 10.1007/s00280-016-2966-1. Epub 2016 Jan 20.

16.

A Case of Endometrioid Adenocarcinoma Originating from the Serous Surface of the Small Intestine.

Makihara N, Fujita I, Soudaf H, Yamamoto T, Sashikata T, Mukohara T, Maeda T.

Rare Tumors. 2015 Sep 30;7(3):5932. doi: 10.4081/rt.2015.5932. eCollection 2015 Sep 7.

17.

[Effect of Natural Killer Cell Infiltration on the Growth of Breast Cancer Patient-Derived Tumor Xenografts].

Mukohyama J, Shimono Y, Funakoshi Y, Kono S, Yamashita K, Mukohara T, Takao S, Minami H, Kakeji Y.

Gan To Kagaku Ryoho. 2015 Oct;42(10):1252-5. Japanese.

PMID:
26489563
18.

Mediastinal Germ Cell Tumor Exhibiting a Discrepancy between Tumor Markers and Imaging: A Case Study.

Takenaka K, Mukohara T, Hirai C, Funakoshi Y, Nakamura Y, Chayahara N, Toyoda M, Kiyota N, Itoh T, Yokozaki H, Minami H.

Case Rep Oncol. 2015 Aug 1;8(2):323-31. doi: 10.1159/000438697. eCollection 2015 May-Aug.

19.

Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide.

Kimbara S, Fujiwara Y, Toyoda M, Chayahara N, Imamura Y, Kiyota N, Mukohara T, Fukunaga A, Oka M, Nishigori C, Minami H.

Clin J Gastroenterol. 2014 Jun;7(3):255-9. doi: 10.1007/s12328-014-0471-9. Epub 2014 Apr 9.

PMID:
26183746
20.

PI3K mutations in breast cancer: prognostic and therapeutic implications.

Mukohara T.

Breast Cancer (Dove Med Press). 2015 May 15;7:111-23. doi: 10.2147/BCTT.S60696. eCollection 2015. Review.

21.

[Toxicity management for mTOR inhibitors].

Mukohara T.

Nihon Rinsho. 2015 Feb;73 Suppl 2:272-6. Japanese. No abstract available.

PMID:
25831766
22.

Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer.

Imamura Y, Mukohara T, Shimono Y, Funakoshi Y, Chayahara N, Toyoda M, Kiyota N, Takao S, Kono S, Nakatsura T, Minami H.

Oncol Rep. 2015 Apr;33(4):1837-43. doi: 10.3892/or.2015.3767. Epub 2015 Jan 29.

PMID:
25634491
23.

Cutaneous endometrial cancer arising from heterotopic endometriosis in an abdominal caesarean section scar.

Tajima S, Bito T, Ikeda T, Mukohara T, Nishigori C.

J Eur Acad Dermatol Venereol. 2016 Apr;30(4):683-5. doi: 10.1111/jdv.12964. Epub 2015 Jan 26. No abstract available.

PMID:
25622645
24.

Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancer.

Fujiwara Y, Kobayashi T, Chayahara N, Imamura Y, Toyoda M, Kiyota N, Mukohara T, Nishiumi S, Azuma T, Yoshida M, Minami H.

PLoS One. 2014 Nov 20;9(11):e113259. doi: 10.1371/journal.pone.0113259. eCollection 2014.

25.

Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.

Fujiwara Y, Toyoda M, Chayahara N, Kiyota N, Shimada T, Imamura Y, Mukohara T, Minami H.

PLoS One. 2014 Aug 14;9(8):e104215. doi: 10.1371/journal.pone.0104215. eCollection 2014.

26.

TYRO3 as a potential therapeutic target in breast cancer.

Ekyalongo RC, Mukohara T, Funakoshi Y, Tomioka H, Kataoka Y, Shimono Y, Chayahara N, Toyoda M, Kiyota N, Minami H.

Anticancer Res. 2014 Jul;34(7):3337-45.

PMID:
24982338
27.

Absence of primary cilia in cell cycle-arrested human breast cancer cells.

Nobutani K, Shimono Y, Yoshida M, Mizutani K, Minami A, Kono S, Mukohara T, Yamasaki T, Itoh T, Takao S, Minami H, Azuma T, Takai Y.

Genes Cells. 2014 Feb;19(2):141-52. doi: 10.1111/gtc.12122. Epub 2013 Dec 12.

28.

Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines.

Fujiwara Y, Chayahara N, Mukohara T, Kiyota N, Tomioka H, Funakoshi Y, Minami H.

Oncol Rep. 2013 Oct;30(4):1802-6. doi: 10.3892/or.2013.2644. Epub 2013 Jul 30.

PMID:
23900774
29.

Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line.

Funakoshi Y, Mukohara T, Tomioka H, Ekyalongo RC, Kataoka Y, Inui Y, Kawamori Y, Toyoda M, Kiyota N, Fujiwara Y, Minami H.

Invest New Drugs. 2013 Oct;31(5):1158-68. doi: 10.1007/s10637-013-9959-2. Epub 2013 Apr 9.

PMID:
23568717
30.

A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors.

Fujiwara Y, Ando Y, Mukohara T, Kiyota N, Chayahara N, Mitsuma A, Inada-Inoue M, Sawaki M, Ilaria R Jr, Kellie Turner P, Funai J, Maeda K, Minami H.

Cancer Chemother Pharmacol. 2013 Apr;71(4):991-8. doi: 10.1007/s00280-013-2092-2. Epub 2013 Feb 1.

PMID:
23370664
31.

Prediction of glomerular filtration rate in cancer patients by an equation for Japanese estimated glomerular filtration rate.

Funakoshi Y, Fujiwara Y, Kiyota N, Mukohara T, Shimada T, Toyoda M, Imamura Y, Chayahara N, Umezu M, Otsuki N, Nibu K, Minami H.

Jpn J Clin Oncol. 2013 Mar;43(3):271-7. doi: 10.1093/jjco/hys235. Epub 2013 Jan 17.

PMID:
23329851
32.

Regulation of MET kinase inhibitor resistance by copy number of MET in gastric carcinoma cells.

Funakoshi Y, Mukohara T, Ekyalongo RC, Tomioka H, Kataoka Y, Shimono Y, Chayahara N, Toyoda M, Kiyota N, Fujiwara Y, Minami H.

Oncol Res. 2013;21(6):287-93. doi: 10.3727/096504014X13946388748956.

PMID:
25198658
33.

Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line.

Ekyalongo RC, Mukohara T, Kataoka Y, Funakoshi Y, Tomioka H, Kiyota N, Fujiwara Y, Minami H.

Invest New Drugs. 2013 Apr;31(2):293-303. doi: 10.1007/s10637-012-9855-1. Epub 2012 Jul 25.

PMID:
22828916
34.

Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification.

Tomioka H, Mukohara T, Kataoka Y, Ekyalongo RC, Funakoshi Y, Imai Y, Kiyota N, Fujiwara Y, Minami H.

Int J Oncol. 2012 Aug;41(2):551-8. doi: 10.3892/ijo.2012.1485. Epub 2012 May 17.

PMID:
22614071
35.

Mediator subunits MED1 and MED24 cooperatively contribute to pubertal mammary gland development and growth of breast carcinoma cells.

Hasegawa N, Sumitomo A, Fujita A, Aritome N, Mizuta S, Matsui K, Ishino R, Inoue K, Urahama N, Nose J, Mukohara T, Kamoshida S, Roeder RG, Ito M.

Mol Cell Biol. 2012 Apr;32(8):1483-95. doi: 10.1128/MCB.05245-11. Epub 2012 Feb 13.

36.

Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer.

Mukohara T.

Chemother Res Pract. 2011;2011:730360. doi: 10.1155/2011/730360. Epub 2011 Sep 25.

37.

First clinical pharmacokinetic dose-escalation study of sagopilone, a novel, fully synthetic epothilone, in Japanese patients with refractory solid tumors.

Araki K, Kitagawa K, Mukai H, Mukohara T, Kodama K, Ando Y, Narabayashi M, Minami H, Mera K, Sasaki Y.

Invest New Drugs. 2012 Dec;30(6):2327-33. doi: 10.1007/s10637-011-9773-7. Epub 2011 Dec 4.

PMID:
22139065
38.

Eribulin mesylate in patients with refractory cancers: a Phase I study.

Mukohara T, Nagai S, Mukai H, Namiki M, Minami H.

Invest New Drugs. 2012 Oct;30(5):1926-33. doi: 10.1007/s10637-011-9741-2. Epub 2011 Sep 2.

39.

Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.

Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, Yashiro M, Hirakawa K, Hirai M, Minami H.

Invest New Drugs. 2012 Aug;30(4):1352-60. doi: 10.1007/s10637-011-9699-0. Epub 2011 Jun 8.

PMID:
21655918
40.

Successful neutrophil engraftment by reduced use of granulocyte colony-stimulating factor after allogeneic hematopoietic stem cell transplantation with mycophenolate mofetil for graft-versus-host disease prophylaxis.

Okamura A, Yakushijin K, Inui Y, Funakoshi Y, Kawamori Y, Shimada T, Toyoda M, Chayahara N, Kiyota N, Fujiwara Y, Mukohara T, Matsuoka H, Yamamoto K, Minami H.

Int J Hematol. 2011 Jun;93(6):765-770. doi: 10.1007/s12185-011-0852-5. Epub 2011 Apr 22.

PMID:
21512728
41.

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.

Fujiwara Y, Kiyota N, Chayahara N, Suzuki A, Umeyama Y, Mukohara T, Minami H.

Invest New Drugs. 2012 Jun;30(3):1055-64. doi: 10.1007/s10637-011-9637-1. Epub 2011 Feb 8.

42.

Left atrial extension of metastatic lung tumor via pulmonary vein: report on the first case of Ewing sarcoma.

Funakoshi Y, Mukohara T, Kataoka T, Tomioka H, Chayahara N, Fujiwara Y, Kiyota N, Shirasaka T, Oka T, Okada K, Okita Y, Hara S, Itoh T, Fumita S, Nakagawa K, Minami H.

Rare Tumors. 2010 Sep 30;2(3):e53. doi: 10.4081/rt.2010.e53.

43.

Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.

Mukohara T.

Cancer Sci. 2011 Jan;102(1):1-8. doi: 10.1111/j.1349-7006.2010.01711.x. Epub 2010 Sep 6. Review.

44.

Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors.

Mukohara T, Nagai S, Koshiji M, Yoshizawa K, Minami H.

Cancer Sci. 2010 Oct;101(10):2193-9. doi: 10.1111/j.1349-7006.2010.01677.x. Epub 2010 Aug 12.

45.

Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients.

Mukohara T, Nakajima H, Mukai H, Nagai S, Itoh K, Umeyama Y, Hashimoto J, Minami H.

Cancer Sci. 2010 Apr;101(4):963-8. doi: 10.1111/j.1349-7006.2009.01465.x. Epub 2009 Dec 9.

46.

Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors.

Yamada K, Yamamoto N, Yamada Y, Mukohara T, Minami H, Tamura T.

Jpn J Clin Oncol. 2010 May;40(5):404-11. doi: 10.1093/jjco/hyp192. Epub 2010 Feb 4.

47.

Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer.

Ishihara M, Mukai H, Nagai S, Mukohara T.

Int J Clin Oncol. 2009 Oct;14(5):431-5. doi: 10.1007/s10147-009-0898-z. Epub 2009 Oct 25.

PMID:
19856052
48.

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.

Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H.

Ann Oncol. 2010 Feb;21(2):255-62. doi: 10.1093/annonc/mdp304. Epub 2009 Jul 24.

PMID:
19633047
49.

Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.

Mukohara T, Shimada H, Ogasawara N, Wanikawa R, Shimomura M, Nakatsura T, Ishii G, Park JO, Jänne PA, Saijo N, Minami H.

Cancer Lett. 2009 Sep 8;282(1):14-24. doi: 10.1016/j.canlet.2009.02.056. Epub 2009 Apr 3.

PMID:
19345478
50.

[Management of toxicity associated with chemotherapy for breast cancer].

Mukohara T, Mukai H.

Nihon Rinsho. 2007 Jun 28;65 Suppl 6:516-22. Review. Japanese. No abstract available.

PMID:
17682204

Supplemental Content

Loading ...
Support Center